Activation of a promyelocytic leukemia–tumor protein 53 axis underlies acute promyelocytic leukemia cure
Authors:
- 12 January 2014
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 20 (2) , 167-174
Abstract
Acute promyelocytic leukemia (APL) is driven by the promyelocytic leukemia (PML)-retinoic acid receptor-α (PML-RARA) fusion protein, which interferes with nuclear receptor signaling and PML nuclear body (NB) assembly. APL is the only malignancy definitively cured by targeted therapies: retinoic acid (RA) and/or arsenic trioxide, which both trigger PML-RARA degradation through nonoverlapping pathways. Yet, the cellular and molecular determinants of treatment efficacy remain disputed. We demonstrate that a functional Pml-transformation-related protein 53 (Trp53) axis is required to eradicate leukemia-initiating cells in a mouse model of APL. Upon RA-induced PML-RARA degradation, normal Pml elicits NB reformation and induces a Trp53 response exhibiting features of senescence but not apoptosis, ultimately abrogating APL-initiating activity. Apart from triggering PML-RARA degradation, arsenic trioxide also targets normal PML to enhance NB reformation, which may explain its clinical potency, alone or with RA. This Pml-Trp53 checkpoint initiated by therapy-triggered NB restoration is specific for PML-RARA-driven APL, but not the RA-resistant promyelocytic leukemia zinc finger (PLZF)-RARA variant. Yet, as NB biogenesis is druggable, it could be therapeutically exploited in non-APL malignancies.Keywords
This publication has 61 references indexed in Scilit:
- The Origin and Evolution of Mutations in Acute Myeloid LeukemiaCell, 2012
- Lamin B1 loss is a senescence-associated biomarkerMolecular Biology of the Cell, 2012
- Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemiaJournal of Experimental Medicine, 2010
- p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewalGenes & Development, 2010
- PML Nuclear BodiesCold Spring Harbor Perspectives in Biology, 2010
- Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemiaProceedings of the National Academy of Sciences, 2009
- The role of the bone marrow in neutrophil clearance under homeostatic conditions in the mouseThe FASEB Journal, 2008
- PML targeting eradicates quiescent leukaemia-initiating cellsNature, 2008
- RARα-PLZF overcomes PLZF-mediated repression of CRABPI , contributing to retinoid resistance in t(11;17) acute promyelocytic leukemiaProceedings of the National Academy of Sciences, 2007
- Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescenceNature Cell Biology, 2006